BEAM
Price
$16.87
Change
+$0.23 (+1.38%)
Updated
Aug 27, 04:59 PM (EDT)
Capitalization
1.68B
74 days until earnings call
MGX
Price
$1.89
Change
+$0.02 (+1.07%)
Updated
Aug 27, 04:59 PM (EDT)
Capitalization
70.19M
77 days until earnings call
Interact to see
Advertisement

BEAM vs MGX

Header iconBEAM vs MGX Comparison
Open Charts BEAM vs MGXBanner chart's image
Beam Therapeutics
Price$16.87
Change+$0.23 (+1.38%)
Volume$18.89K
Capitalization1.68B
Metagenomi
Price$1.89
Change+$0.02 (+1.07%)
Volume$542
Capitalization70.19M
BEAM vs MGX Comparison Chart in %
Loading...
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BEAM vs. MGX commentary
Aug 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Buy and MGX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 28, 2025
Stock price -- (BEAM: $16.86 vs. MGX: $1.86)
Brand notoriety: BEAM and MGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 63% vs. MGX: 19%
Market capitalization -- BEAM: $1.68B vs. MGX: $70.19M
BEAM [@Biotechnology] is valued at $1.68B. MGX’s [@Biotechnology] market capitalization is $70.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileMGX’s FA Score has 1 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • MGX’s FA Score: 1 green, 4 red.
According to our system of comparison, MGX is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 3 TA indicator(s) are bullish while MGX’s TA Score has 4 bullish TA indicator(s).

  • BEAM’s TA Score: 3 bullish, 6 bearish.
  • MGX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, MGX is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а +4.98% price change this week, while MGX (@Biotechnology) price change was +0.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.04%. For the same industry, the average monthly price growth was +19.75%, and the average quarterly price growth was +30.54%.

Reported Earning Dates

BEAM is expected to report earnings on Nov 10, 2025.

MGX is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+4.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($1.68B) has a higher market cap than MGX($70.2M). BEAM YTD gains are higher at: -32.016 vs. MGX (-48.199). MGX has higher annual earnings (EBITDA): -86.3M vs. BEAM (-414.33M). BEAM has more cash in the bank: 1.15B vs. MGX (205M). MGX has less debt than BEAM: MGX (43M) vs BEAM (155M). BEAM has higher revenues than MGX: BEAM (60.3M) vs MGX (33.8M).
BEAMMGXBEAM / MGX
Capitalization1.68B70.2M2,397%
EBITDA-414.33M-86.3M480%
Gain YTD-32.016-48.19966%
P/E RatioN/AN/A-
Revenue60.3M33.8M178%
Total Cash1.15B205M561%
Total Debt155M43M360%
TECHNICAL ANALYSIS
Technical Analysis
BEAMMGX
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
78%
Bullish Trend 15 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LSSNX30.670.19
+0.62%
Loomis Sayles Small Cap Growth N
CIHEX18.540.04
+0.22%
Calamos Hedged Equity I
ODMAX44.59N/A
N/A
Invesco Developing Markets A
AIGOX36.47N/A
N/A
Alger Growth & Income I-2
NMULX11.32N/A
N/A
Neuberger Berman Multi-Cap Opp I

MGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGX has been loosely correlated with KOD. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if MGX jumps, then KOD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGX
1D Price
Change %
MGX100%
-0.53%
KOD - MGX
41%
Loosely correlated
+2.22%
SABS - MGX
36%
Loosely correlated
-2.26%
CVM - MGX
35%
Loosely correlated
+7.01%
CDXS - MGX
34%
Loosely correlated
-1.87%
BEAM - MGX
34%
Loosely correlated
+1.22%
More